Navigation Links
Nature's Bioceuticals Develops New Formula For Men With Enlarged Prostate
Date:12/8/2011

CAPE CORAL, Fla., Dec. 8, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures, Inc. (MILV.pk) announced that it has developed a new formula that promotes prostate health.

According to the National Institutes of Health (NIH), enlarged prostate — clinically known as benign prostatic hyperplasia (BPH) — is a "common part of aging" for men. In fact, the NIH estimates that "more than half of men in their 60s, and as many as 90% in their 70s and 80s, have some symptoms of BPH. The condition often leads to urinary incontinence and can raise the odds for urinary tract infections and even kidney damage.

Robert deZanger, CEO of Natures Bioceuticals stated, "We are pleased to add the Prostate Formula to our line of natural medicines. This formula will provide comfort and a better quality of life to men around the globe. Many men start developing symptoms in their late thirties and the likelihood of developing BPH increases with age. This is another product for which there is a huge market and capturing a small percentage can generate substantial profits for the company."

The Formula was developed by Nature's Bioceuticals in collaboration with the inventor of its Kidney Formula. Men testing the kidney formula noticed that it reduced the size of their prostate and that the symptoms normally associated with enlarged prostate glands began to diminish. They experienced the return of a stronger urinary stream and a decrease in urgency, leaking or dribbling and less frequent urination allowing a more restful sleep.  Encouraged by the positive side effects the new prostate formula was developed using the kidney formula as a base and adding a number of additional natural ingredients which target the prostate gland.

About Nature's Bioceuticals:
Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA".

In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com


'/>"/>
SOURCE Mistral Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
2. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
3. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
4. Natures Bioceuticals Finalizes Agreement for the Purchase of Proprietary Weight Loss Formula
5. Natures Bioceuticals Finalizes The Purchase of Cold and Flu Formula
6. Natures Bioceuticals Tears Into the Multi-Billion Dollar Chronic Kidney Disease Market
7. Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands
8. MedBox Develops Patent-Pending System for Storage and Retrieval of Prescription Drugs
9. Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients
10. Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs
11. Unilife Develops Unifill® EZMix Multiple-Chamber Prefilled Syringes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Period October – December 2016 ... to SEK -16.4 (-6.4) million Result after tax amounted to ... after dilution Cash flow from operating activities amounted to SEK ... Period full ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Mass. , Feb. 24, 2017  Today, ... US dental labs have a new path to ... using the Biodenta implant library integrated into exocad ... must implement FDA compliant Good Manufacturing Processes (GMP,s) ... manufacturer with Biodenta, and complete an audit process. Then, ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... ... is proud to announce a new informational post on robotic hair transplantation. San ... Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either ...
(Date:2/26/2017)... Como, Italy (PRWEB) , ... February 26, 2017 ... ... its last call for entries to the 7th Edition of International Social Design ... by Social Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with ...
(Date:2/26/2017)... PA (PRWEB) , ... February 26, 2017 , ... ... and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. ... Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is ... specific LRRK2 mutation, according to a study released today at the 1st Pan ... a link between pesticides and incidence of sporadic PD through occupational exposure. This ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):